Iterum Therapeutics (ITRM) Gains from Investment Securities (2017 - 2022)
Historic Gains from Investment Securities for Iterum Therapeutics (ITRM) over the last 6 years, with Q4 2022 value amounting to $101000.0.
- Iterum Therapeutics' Gains from Investment Securities rose 11071.05% to $101000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was -$1.9 million, marking a year-over-year increase of 1300.32%. This contributed to the annual value of -$3.9 million for FY2024, which is 7022.5% down from last year.
- Iterum Therapeutics' Gains from Investment Securities amounted to $101000.0 in Q4 2022, which was up 11071.05% from $329799.0 recorded in Q3 2022.
- Over the past 5 years, Iterum Therapeutics' Gains from Investment Securities peaked at $18.3 million during Q2 2022, and registered a low of -$1.2 million during Q1 2022.
- Over the past 5 years, Iterum Therapeutics' median Gains from Investment Securities value was $693422.5 (recorded in 2018), while the average stood at $2.6 million.
- Its Gains from Investment Securities has fluctuated over the past 5 years, first surged by 387732.83% in 2018, then crashed by 188965.52% in 2019.
- Iterum Therapeutics' Gains from Investment Securities (Quarter) stood at -$58000.0 in 2018, then plummeted by 1889.66% to -$1.2 million in 2019, then surged by 113.43% to $155000.0 in 2020, then plummeted by 708.39% to -$943000.0 in 2021, then skyrocketed by 110.71% to $101000.0 in 2022.
- Its last three reported values are $101000.0 in Q4 2022, $329799.0 for Q3 2022, and $18.3 million during Q2 2022.